MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

By Daphne Psaledakis and Simon Lewis WASHINGTON (Reuters) -About 1,000 doses of Gilead Sciences Inc's drug lenacapavir were ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

The U.S. Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV. The drug, called Yeztugo from company Gilead Sciences, was approved Wednesday based ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

Lenacapavir is an injectable medicine that only needs to be taken twice a year, making it easier to use than daily HIV pills.

The US delivers Lenacapavir HIV treatment to Eswatini and Zambia, expanding prevention efforts despite prior aid cuts under ...

Amid steep cuts to U.S. foreign assistance, the Trump administration is touting a new plan to provide a powerful HIV ...